The importance of myocardial protection in combined aortic valve replacement and myocardial revascularization
Related Experiment Videos
Insights
Cold chemical cardioplegia significantly improved outcomes for patients undergoing combined aortic valve replacement and coronary revascularization. This myocardial protection method reduced mortality and myocardial injury compared to coronary perfusion.
Area of Science:
- Cardiology
- Cardiac Surgery
- Cardiovascular Research
Background:
- Combined aortic valve replacement and coronary revascularization is a complex procedure.
- Patients often present with severe symptoms like angina and left ventricular impairment.
- Effective myocardial protection is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of different myocardial protection strategies.
- To compare outcomes between intermittent ischemia, coronary perfusion, and cold chemical cardioplegia.
- To determine the optimal method for myocardial protection in this patient population.
Main Methods:
- Retrospective analysis of 82 patients undergoing combined procedures (1973-1978).
- Patients were divided into groups based on myocardial protection: intermittent ischemia (Group I), coronary perfusion (Group IIa/IIb), and cold chemical cardioplegia (Group III).
- Outcomes assessed included early mortality, perioperative myocardial infarction, and cardiogenic shock.
Main Results:
- Early mortality was 50% (Group I) and 29% (Group IIa), with 0% in Group IIb and Group III.
- Perioperative myocardial infarction rates were 21% (Group I), 6% (Group IIa), 11% (Group IIb), and 0% (Group III).
- Cold chemical cardioplegia (Group III) showed significantly lower rates of cardiogenic shock (9%) compared to coronary perfusion (Group IIb, 50%).
Conclusions:
- Cold chemical cardioplegia offers superior myocardial protection compared to coronary perfusion.
- This method significantly reduces perioperative myocardial infarction and cardiogenic shock.
- Findings support the use of cold chemical cardioplegia for improved outcomes in combined aortic valve replacement and coronary revascularization.
Abstract:
To determine the importance of different methods of myocardial protection for combined aortic valve replacement and coronary revascularization, we analyzed the records of 82 consecutive patients who underwent the combined procedure between 1973 and 1978. Sixty-three (77%) had angina and 63 (77%) were in New York Heart Association Functional Class III or IV. Moderate to severe left ventricular impairment was present in 59%, and the mean number of diseased vessels was 1.9 per patient. Group I consisted of 18 patients with intermittent ischemia, almost all of whom had operation between 1973 and 1976. Group IIa consisted of 24 patients operated on between 1973 and December, 1976, with coronary perfusion, and Group IIb had 18 patients in whom a similar technique was used in 1977 and 1978. Group III consisted of 22 patients operated on in 1977 and 1978 in whom cold chemical cardioplegia was used. The early mortality (less than 30 days) for Group I was 50% and for Group IIa 29%. There were no deaths in Group IIb and Group III. The incidence of perioperative myocardial infarction was 21% in Group I, 6% in Group IIa, 11% in Group IIb, and zero in Group III. The incidence of cardiogenic shock requiring prolonged inotropic support and intraaortic balloon counterpulsation was significantly less in Group III (9%) than in Group IIb (50%) (p less than 0.05). If other manifestations of myocardial injury, such as perioperative infarction and cardiogenic shock requiring intraaortic balloon counterpulsation or inotropic support, are taken into consideration, cold chemical cardioplegia appears to provide better myocardial protection than coronary perfusion of the fibrillating heart.